141 related articles for article (PubMed ID: 25305404)
21. [Neurogenic or idiopathic destrusor overactivity after failed antimuscarinic treatment : clinical value of external temporary electrostimulation].
Pannek J; Janek S; Noldus J
Urologe A; 2010 Apr; 49(4):530-5. PubMed ID: 20057991
[TBL] [Abstract][Full Text] [Related]
22. Animal models of sacral neuromodulation for detrusor overactivity.
Vignes JR; Deloire M; Petry K
Neurourol Urodyn; 2009; 28(1):8-12. PubMed ID: 18785181
[TBL] [Abstract][Full Text] [Related]
23. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence.
Kuo HC; Liu HT; Chancellor MB
Neurourol Urodyn; 2010 Mar; 29(3):482-7. PubMed ID: 19367641
[TBL] [Abstract][Full Text] [Related]
24. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
van Gool JD; de Jong TP; Winkler-Seinstra P; Tamminen-Möbius T; Lax H; Hirche H; Nijman RJ; Hjälmås K; Jodal U; Bachmann H; Hoebeke P; Walle JV; Misselwitz J; John U; Bael A;
Neurourol Urodyn; 2014 Jun; 33(5):482-7. PubMed ID: 23775924
[TBL] [Abstract][Full Text] [Related]
25. [Not Available].
Bywater M; Kessler TM
Praxis (Bern 1994); 2017; 106(21):1175-1181. PubMed ID: 29041854
[No Abstract] [Full Text] [Related]
26. Three-year Follow-up Results of a Prospective, Multicenter Study in Overactive Bladder Subjects Treated With Sacral Neuromodulation.
Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Thiery E
Urology; 2016 Aug; 94():57-63. PubMed ID: 27131966
[TBL] [Abstract][Full Text] [Related]
27. Does sex matter? A matched pairs analysis of neuromodulation outcomes in women and men.
Nguyen LN; Bartley J; Killinger KA; Gupta P; Lavin J; Khourdaji A; Gilleran J; Gaines N; Boura JA; Peters KM
Int Urol Nephrol; 2018 May; 50(5):825-832. PubMed ID: 29532309
[TBL] [Abstract][Full Text] [Related]
28. Sacral neuromodulation in urological indications: the Finnish experience.
Vaarala MH; Tammela TL; Perttilä I; Luukkonen P; Hellström P
Scand J Urol Nephrol; 2011 Feb; 45(1):46-51. PubMed ID: 20961268
[TBL] [Abstract][Full Text] [Related]
29. Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women.
Yazdany T; Bhatia N; Nguyen J
Int Urogynecol J; 2011 Dec; 22(12):1549-54. PubMed ID: 21796469
[TBL] [Abstract][Full Text] [Related]
30. Best treatment for overactive bladder if behavioral treatment and anticholinergics fail. Sacral nerve stimulation.
Griebling TL
J Urol; 2011 Jun; 185(6):2024-6. PubMed ID: 21507425
[No Abstract] [Full Text] [Related]
31. Urinary disorders and female sexual function.
Chen J; Sweet G; Shindel A
Curr Urol Rep; 2013 Aug; 14(4):298-308. PubMed ID: 23716031
[TBL] [Abstract][Full Text] [Related]
32. Central inhibition of refractory overactive bladder complaints, results of an inpatient training program.
Meijer EF; Nieuwhof-Leppink AJ; Dekker-Vasse E; de Joode-Smink GC; de Jong TP
J Pediatr Urol; 2015 Feb; 11(1):21.e1-5. PubMed ID: 25205144
[TBL] [Abstract][Full Text] [Related]
33. The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children.
Bael A; Lax H; de Jong TP; Hoebeke P; Nijman RJ; Sixt R; Verhulst J; Hirche H; van Gool JD;
J Urol; 2008 Oct; 180(4):1486-93; discussion 1494-5. PubMed ID: 18710726
[TBL] [Abstract][Full Text] [Related]
34. Effect of tibial nerve stimulation on bladder afferent nerve activity in a rat detrusor overactivity model.
Choudhary M; van Mastrigt R; van Asselt E
Int J Urol; 2016 Mar; 23(3):253-8. PubMed ID: 26690557
[TBL] [Abstract][Full Text] [Related]
35. Re: Long Term Safety of Sacral Nerve Modulation in Medicare Beneficiaries.
Griebling TL
J Urol; 2015 Oct; 194(4):1054-5. PubMed ID: 26382804
[No Abstract] [Full Text] [Related]
36. Sacral Nerve Stimulation for Pediatric Lower Urinary Tract Dysfunction: Development of a Standardized Pathway with Objective Urodynamic Outcomes.
Schober MS; Sulkowski JP; Lu PL; Minneci PC; Deans KJ; Teich S; Alpert SA
J Urol; 2015 Dec; 194(6):1721-6. PubMed ID: 26141849
[TBL] [Abstract][Full Text] [Related]
37. Actual treatment of overactive bladder and urge urinary incontinence.
Cornu JN
Minerva Urol Nefrol; 2013 Mar; 65(1):21-35. PubMed ID: 23538308
[TBL] [Abstract][Full Text] [Related]
38. Predictors of persistent detrusor overactivity after transvaginal sling procedures.
Gamble TL; Botros SM; Beaumont JL; Goldberg RP; Miller JJ; Adeyanju O; Sand PK
Am J Obstet Gynecol; 2008 Dec; 199(6):696.e1-7. PubMed ID: 18845297
[TBL] [Abstract][Full Text] [Related]
39. [Using autonomous electrostimulation device Erektron in treating female overactive bladder].
Yarin GY; Shelyakina OV; Fedorenko VN; Alekseeva AV; Vilgelmi IA
Urologiia; 2016 Nov; (5):43-46. PubMed ID: 28248019
[TBL] [Abstract][Full Text] [Related]
40. Urodynamic findings in women with refractory overactive bladder symptoms.
Al-Zahrani AA; Gajewski J
Int J Urol; 2016 Jan; 23(1):75-9. PubMed ID: 26417863
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
